Amphotericin B
- Generic Name
- Amphotericin B
- Brand Names
- Abelcet, Ambisome, Amphotec, Fungizone
- Drug Type
- Small Molecule
- Chemical Formula
- C47H73NO17
- CAS Number
- 1397-89-3
- Unique Ingredient Identifier
- 7XU7A7DROE
- Background
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
- Indication
Used to treat potentially life threatening fungal infections.
- Associated Conditions
- Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Liposome
- Registration Number
- NCT00002019
- Locations
- 🇺🇸
Univ TX Galveston Med Branch, Galveston, Texas, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Cornell Univ Med College, New York, New York, United States
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002305
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ School of Medicine, Atlanta, Georgia, United States
🇺🇸DeKalb Gen Hosp, Decatur, Georgia, United States
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
- Conditions
- MycosesHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002277
- Locations
- 🇺🇸
Dr Temple Williams, Houston, Texas, United States
🇺🇸M D Anderson Cancer Ctr, Houston, Texas, United States
🇺🇸Dr Layne Gentry, Houston, Texas, United States
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
- Conditions
- Candidiasis, EsophagealHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002041
- Locations
- 🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002074
- Locations
- 🇺🇸
Dr Richard Meyer, Los Angeles, California, United States
🇺🇸DeKalb Gen Hosp, Decatur, Georgia, United States
🇺🇸Shallowford Hosp, Decatur, Georgia, United States
A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002068
- Locations
- 🇺🇸
Christiana Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States
🇺🇸Univ of Tennessee, Memphis, Tennessee, United States
🇺🇸Davies Med Ctr, San Francisco, California, United States
Dexamethasone in Cryptococcal Meningitis
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 36
- Registration Number
- NCT00000776
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- InterMune
- Target Recruit Count
- 60
- Registration Number
- NCT00012467
- Locations
- 🇺🇸
Houston Veterans Administration Med Ctr, Houston, Texas, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
🇵🇪Instituto de Medicina Tropical, Lima, Peru
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.